Chartwell Investment Partners LLC Boosts Position in Neurocrine Biosciences, Inc. (NBIX)
Chartwell Investment Partners LLC increased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 5.1% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 73,428 shares of the company’s stock after purchasing an additional 3,532 shares during the quarter. Chartwell Investment Partners LLC owned 0.08% of Neurocrine Biosciences worth $4,499,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Janus Henderson Group PLC bought a new position in shares of Neurocrine Biosciences during the 2nd quarter worth approximately $246,888,000. TimesSquare Capital Management LLC grew its stake in shares of Neurocrine Biosciences by 299.4% during the 2nd quarter. TimesSquare Capital Management LLC now owns 2,315,373 shares of the company’s stock worth $106,507,000 after acquiring an additional 1,735,700 shares in the last quarter. HealthCor Management L.P. grew its stake in shares of Neurocrine Biosciences by 108.2% during the 2nd quarter. HealthCor Management L.P. now owns 2,550,178 shares of the company’s stock worth $117,308,000 after acquiring an additional 1,325,178 shares in the last quarter. FMR LLC boosted its holdings in shares of Neurocrine Biosciences by 9.8% in the 2nd quarter. FMR LLC now owns 13,211,023 shares of the company’s stock valued at $607,707,000 after buying an additional 1,180,874 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Neurocrine Biosciences by 53.3% in the 2nd quarter. Goldman Sachs Group Inc. now owns 2,674,217 shares of the company’s stock valued at $123,014,000 after buying an additional 930,268 shares during the last quarter.
In related news, insider Haig P. Bozigian sold 26,250 shares of Neurocrine Biosciences stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $1,575,000.00. Following the completion of the sale, the insider now owns 144,601 shares of the company’s stock, valued at $8,676,060. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Christopher Flint Obrien sold 6,925 shares of Neurocrine Biosciences stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $61.04, for a total value of $422,702.00. Following the completion of the sale, the insider now directly owns 55,898 shares of the company’s stock, valued at approximately $3,412,013.92. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 150,710 shares of company stock valued at $9,758,593. 4.80% of the stock is owned by corporate insiders.
Shares of Neurocrine Biosciences, Inc. (NASDAQ NBIX) traded down $2.38 on Thursday, reaching $71.81. The company had a trading volume of 673,283 shares, compared to its average volume of 1,115,928. The company has a debt-to-equity ratio of 1.05, a quick ratio of 14.37 and a current ratio of 14.38. Neurocrine Biosciences, Inc. has a twelve month low of $37.35 and a twelve month high of $75.98.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.36. The firm had revenue of $60.77 million for the quarter, compared to the consensus estimate of $29.38 million. During the same quarter last year, the company posted ($0.43) earnings per share. research analysts expect that Neurocrine Biosciences, Inc. will post -1.74 EPS for the current year.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).
Receive News & Stock Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related stocks with our FREE daily email newsletter.